image
Healthcare - Biotechnology - NASDAQ - US
$ 14.54
1.68 %
$ 948 M
Market Cap
-3.88
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one MLYS stock under the worst case scenario is HIDDEN Compared to the current market price of 14.5 USD, Mineralys Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one MLYS stock under the base case scenario is HIDDEN Compared to the current market price of 14.5 USD, Mineralys Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one MLYS stock under the best case scenario is HIDDEN Compared to the current market price of 14.5 USD, Mineralys Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MLYS

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-192 M OPERATING INCOME
-127.27%
-178 M NET INCOME
-147.31%
-166 M OPERATING CASH FLOW
-104.89%
115 M INVESTING CASH FLOW
171.64%
116 M FINANCING CASH FLOW
-42.86%
0 REVENUE
0.00%
-44.4 M OPERATING INCOME
14.14%
-42.2 M NET INCOME
13.76%
-45.5 M OPERATING CASH FLOW
31.95%
-92.9 M INVESTING CASH FLOW
-111.14%
189 M FINANCING CASH FLOW
210210.00%
Balance Sheet Mineralys Therapeutics, Inc.
image
Current Assets 205 M
Cash & Short-Term Investments 198 M
Receivables 0
Other Current Assets 7.16 M
Non-Current Assets 552 K
Long-Term Investments 0
PP&E 53 K
Other Non-Current Assets 499 K
96.25 %3.48 %Total Assets$205.9m
Current Liabilities 14.6 M
Accounts Payable 479 K
Short-Term Debt 0
Other Current Liabilities 14.2 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
3.27 %96.73 %Total Liabilities$14.6m
EFFICIENCY
Earnings Waterfall Mineralys Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 192 M
Operating Income -192 M
Other Expenses -14.6 M
Net Income -178 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)000(192m)(192m)15m(178m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-92.97% ROE
-92.97%
-86.36% ROA
-86.36%
-100.60% ROIC
-100.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mineralys Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)20212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -178 M
Depreciation & Amortization 43 K
Capital Expenditures -96 K
Stock-Based Compensation 11.3 M
Change in Working Capital 9.52 M
Others -307 K
Free Cash Flow -166 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mineralys Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for MLYS of $42 , with forecasts ranging from a low of $30 to a high of $48 .
MLYS Lowest Price Target Wall Street Target
30 USD 106.33%
MLYS Average Price Target Wall Street Target
42 USD 188.86%
MLYS Highest Price Target Wall Street Target
48 USD 230.12%
Price
Max Price Target
Min Price Target
Average Price Target
50504545404035353030252520201515101055Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Mineralys Therapeutics, Inc.
image
Sold
0-3 MONTHS
821 K USD 3
3-6 MONTHS
1.14 M USD 3
6-9 MONTHS
811 K USD 3
9-12 MONTHS
7.54 M USD 4
Bought
0 USD 0
0-3 MONTHS
37.2 M USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat – The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – globenewswire.com - 1 week ago
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p6.0 mmol/L) 0/59 (0%) 3/58 (5%)   BP, blood pressure; UACR, Urine albumin-to-creatinine ratio; TEAE, Treatment-emergent adverse event * Primary endpoint. ** Cystatin-C formula, a surrogate biomarker of renal function not subject to MATE1 transport and elimination in the glomeruli of the kidney. globenewswire.com - 2 weeks ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) – Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – globenewswire.com - 1 month ago
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 1 month ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025), which will be held in Milan at the MICO Congress Center, on May 23-26, 2025. globenewswire.com - 1 month ago
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 1 month ago
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medical Officer Adam Levy - CFO Conference Call Participants Michael DiFiore - Evercore ISI Richard Law - Goldman Sachs Seamus Fernandez - Guggenheim Rami Katkhuda - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode. seekingalpha.com - 1 month ago
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa. globenewswire.com - 1 month ago
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025. globenewswire.com - 2 months ago
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. globenewswire.com - 2 months ago
Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season. 247wallst.com - 2 months ago
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) – Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – globenewswire.com - 2 months ago
8. Profile Summary

Mineralys Therapeutics, Inc. MLYS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 948 M
Dividend Yield 0.00%
Description Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Contact 150 N. Radnor Chester Rd., Radnor, PA, 19087 https://mineralystx.com
IPO Date Feb. 10, 2023
Employees 51
Officers Dr. Robert McKean Ph.D. Senior Vice President of CMC Mr. Jeffrey N. Fellows Senior Vice President of Regulatory Affairs Ms. Jessica Ibbitson Senior Vice President of Clinical Operations Ms. Danielle Bradbury Senior Vice President of Quality Assurance Ms. Sarah Foster Vice President of Human Resources Mr. Jon Congleton President, Chief Executive Officer & Director Mr. Adam Scott Levy Chief Financial Officer & Secretary Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. Founder & Executive Director Dr. David M. Rodman M.D. Chief Medical Officer Ms. Cindy Berejikian Executive Vice President of Operations